Assenagon Asset Management
NBIX icon

Assenagon Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Assenagon Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5M Buy
222,606
+131,128
+143% +$19.5M 0.05% 290
2026
Q1 		$12.1M Buy
91,478
+11,466
+14% +$1.52M 0.02% 420
2025
Q4 		$11.3M Buy
80,012
+33,065
+70% +$4.79M 0.02% 485
2025
Q3 		$6.59M Sell
46,947
-13,280
-22% -$1.8M 0.01% 565
2025
Q2 		$7.57M Sell
60,227
-333,228
-85% -$38.2M 0.01% 504
2025
Q1 		$43.5M Buy
393,455
+367,315
+1,405% +$46.5M 0.07% 230
2024
Q4 		$3.57M Sell
26,140
-3,663
-12% -$453K 0.01% 777
2024
Q3 		$3.43M Sell
29,803
-219,621
-88% -$30.1M 0.01% 806
2024
Q2 		$34.3M Sell
249,424
-88,313
-26% -$12.1M 0.08% 196
2024
Q1 		$46.6M Buy
337,737
+22,177
+7% +$3.03M 0.11% 150
2023
Q4 		$41.6M Sell
315,560
-268,979
-46% -$31M 0.11% 152
2023
Q3 		$65.8M Buy
584,539
+319,564
+121% +$33.7M 0.2% 85
2023
Q2 		$25M Buy
264,975
+174,467
+193% +$17M 0.09% 192
2023
Q1 		$9.16M Sell
90,508
-117,923
-57% -$12.3M 0.03% 407
2022
Q4 		$24.9M Buy
208,431
+123,613
+146% +$14.5M 0.09% 216
2022
Q3 		$9.01M Sell
84,818
-54,653
-39% -$5.55M 0.03% 365
2022
Q2 		$13.6M Buy
139,471
+125,611
+906% +$11.6M 0.05% 304
2022
Q1 		$1.3M Sell
13,860
-71,965
-84% -$6.1M ﹤0.01% 985
2021
Q4 		$7.31M Buy
85,825
+74,634
+667% +$6.87M 0.02% 412
2021
Q3 		$1.07M Sell
11,191
-37,878
-77% -$3.58M ﹤0.01% 889
2021
Q2 		$4.78M Buy
49,069
+45,836
+1,418% +$4.39M 0.02% 493
2021
Q1 		$314K Buy
+3,233
New +$339K ﹤0.01% 1095
2020
Q3 		– Sell
-22,926
Closed -$2.8M – 1278
2020
Q2 		$2.8M Buy
+22,926
New +$2.53M 0.02% 490
2019
Q4 		– Sell
-24,885
Closed -$2.24M – 878
2019
Q3 		$2.24M Buy
+24,885
New +$2.32M 0.02% 384

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Assenagon Asset Management's NBIX Position: Q2 2026 in Review

Assenagon Asset Management increased its Neurocrine Biosciences (NBIX) stake by 143% in Q2 2026, buying an estimated $19.5M and bringing the position to 222,606 shares worth $37.5M. The position accounts for 0.05% of the portfolio, ranked #290.

Assenagon Asset Management first reported a position in NBIX in Q3 2019 and has held it in 24 quarters since. The position peaked at $65.8M in Q3 2023. 129 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Assenagon Asset Management held 222,606 shares of Neurocrine Biosciences worth $37.5M as of Q2 2026.
  • Assenagon Asset Management bought 131,128 Neurocrine Biosciences shares in Q2 2026, an estimated $19.5M.
  • Neurocrine Biosciences made up 0.05% of Assenagon Asset Management's portfolio in Q2 2026, its #290 holding.
  • Assenagon Asset Management first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 24 quarters since.
  • Assenagon Asset Management's Neurocrine Biosciences position peaked at $65.8M in Q3 2023.
  • 129 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.